Analysis of tumor immunogenicity in germline BRCA1/2 mutation associated breast and ovarian cancers

被引：0
|
作者：
Kraya, Adam [1 ]
Maxwell, Kara N. [1 ]
Wenz, Brandon M. [1 ]
Wubbenhorst, Bradley [1 ]
De Sloover, Daniel [1 ]
Lunceford, Nicole [1 ]
Barrett, Amanda [1 ]
Morrissette, Jennifer D. [1 ]
Feldman, Michael [1 ]
Vonderheide, Robert H. [1 ]
Domcheck, Susan M. [1 ]
Nathanson, Katherine L. [1 ]
机构：
[1] Univ Penn, Philadelphia, PA 19104 USA
来源：
CANCER IMMUNOLOGY RESEARCH | 2017年 / 5卷 / 03期
关键词：
D O I：
10.1158/2326-6074.TUMIMM16-A12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A12
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Copy number variation in recurrent BRCA1/2 germline mutation-associated breast and ovarian cancers
    Shah, Jennifer Brady
    Wubbenhorst, Bradley
    Pluta, John
    Feltcher, Caitlin
    Schmucker, Lauren
    D'Andrea, Kurt
    Symecko, Heather
    Ruan, Catherine
    Nayak, Anupma
    Maxwell, Kara N.
    Domchek, Susan
    Nathanson, Katherine L.
    CANCER RESEARCH, 2020, 80 (16)
  • [2] Somatic mutation profiling of advanced breast and ovarian cancers according to germline BRCA1/2 mutation status
    Stjepanovic, Neda
    Wilson, Michelle K.
    Oza, Amit M.
    Clarke, Blaise
    Berman, Hal K.
    Amir, Eitan
    Mackay, Helen
    Shaw, Patricia
    Butler, Marcus O.
    Mulligan, Anna Marie
    Milea, Anca
    Ahmed, Lailah
    Volenik, Alexandra
    Wang, Lisa
    Pugh, Trevor John
    Stockley, Tracy
    Kim, Raymond H.
    Siu, Lillian L.
    Kamel-Reid, Suzanne
    Bedard, Philippe L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers
    Ewa Przybytkowski
    Thomas Davis
    Abdelrahman Hosny
    Julia Eismann
    Ursula A. Matulonis
    Gerburg M. Wulf
    Sheida Nabavi
    BMC Cancer, 20
  • [4] An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers
    Przybytkowski, Ewa
    Davis, Thomas
    Hosny, Abdelrahman
    Eismann, Julia
    Matulonis, Ursula A.
    Wulf, Gerburg M.
    Nabavi, Sheida
    BMC CANCER, 2020, 20 (01)
  • [5] Germline BRCA1 mutation analysis in Indian breast/ovarian cancer families
    Kumar, BV
    Lakhotia, S
    Ankathil, R
    Madhavan, J
    Jayaprakash, PG
    Nair, MK
    Somasundaram, K
    CANCER BIOLOGY & THERAPY, 2002, 1 (01) : 18 - 21
  • [6] Germline mutation analysis of BRCA1 and BRCA2 genes in Yugoslav breast/ovarian cancer families
    Papp, J
    Raicevic, L
    Milasin, J
    Dimitrijevic, B
    Radulovic, S
    Olah, E
    ONCOLOGY REPORTS, 1999, 6 (06) : 1435 - 1438
  • [7] MUTATION ANALYSIS OF THE BRCA1 GENE IN OVARIAN CANCERS
    TAKAHASHI, H
    BEHBAKHT, K
    MCGOVERN, PE
    CHIU, HC
    COUCH, FJ
    WEBER, BL
    FRIEDMAN, LS
    KING, MC
    FURUSATO, M
    LIVOLSI, VA
    MENZIN, AW
    LIU, PC
    BENJAMIN, I
    MORGAN, MA
    KING, SA
    REBANE, BA
    CARDONICK, A
    MIKUTA, JJ
    RUBIN, SC
    BOYD, J
    CANCER RESEARCH, 1995, 55 (14) : 2998 - 3002
  • [8] Overexpression of BRCA1-IRIS protein in familial ovarian cancers with no BRCA1 or BRCA2 germline mutation
    Boustany, R.
    Pautier, P.
    Rey, A.
    Delaloge, S.
    Chompret, A.
    Bressac-De Paillerets, B.
    ElShamy, W. M.
    Livingston, D. M.
    Feunteun, J.
    Spatz, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation
    Strumidlo, Agnieszka
    Skiba, Sylwia
    Scott, Rodney J.
    Lubinski, Jan
    HEREDITARY CANCER IN CLINICAL PRACTICE, 2017, 15
  • [10] The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation
    Agnieszka Strumidło
    Sylwia Skiba
    Rodney J. Scott
    Jan Lubiński
    Hereditary Cancer in Clinical Practice, 15
12345